AGN Allergan plc

186.37
+0.29  (+0%)
Previous Close 186.08
Open 186.4
Price To Book 1.05
Market Cap 61,181,047,110
Shares 328,277,336
Volume 1,460,418
Short Ratio 4.48
Av. Daily Volume 2,128,039
Stock charts supplied by TradingView

NewsSee all news

  1. Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine

    DUBLIN, Dec. 4, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the efficacy, safety and tolerability of

  2. Announcement under the Irish Takeover Rules: Relevant Securities in Issue - November 29, 2019

    DUBLIN, Nov. 29, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE

  3. Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in The Journal of the American Medical Association

    DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that positive results from ACHIEVE II (UBR-MD-02), a pivotal Phase 3 clinical trial evaluating the efficacy, safety and tolerability of

  4. Allergan® Announces First Annual National BOTOX® Cosmetic (onabotulinumtoxinA) Day

    DUBLIN, Nov. 18, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN), the maker of BOTOX® Cosmetic, has announced the first-ever National BOTOX® Cosmetic Day kicking off on November 20. The celebration recognizes the impact

  5. Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

    - Exicure to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones - Exicure to Host Conference Call Today at 8:30am ET/7:30am CT Exicure, Inc., (NASDAQ:XCUR) a pioneer in gene regulatory

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval (third indication) announced October 3, 2017.
Botox
Forehead lines
Phase 2 trial to be completed 2H 2019.
RTGel in combination with BOTOX
Overactive Bladder (OAB)
Approval announced March 20, 2017.
JUVÉDERM VOLLURE
Correction of moderate to severe facial wrinkles and folds
Phase 3 ongoing.
Brazikumab
Crohn's disease
Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Botox
Depression
Phase 2b trial ongoing.
RORγt agonist
Psoriasis
Approval announced November 13, 2017.
Cariprazine
Maintenance Treatment of Schizophrenia
BLA filing due 1Q 2020.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
Phase 3 data due in 2020.
ATOGEPANT
Chronic migraine
Phase 3 trials did not meet primary endpoints - March 6, 2019.
RAPASTINEL
Major depressive disorder (MDD)
Phase 3 top-line data due 2020.
RELAMORELIN
Diabetic Gastroparesis
CRL issued August 21, 2018.
ESMYA (ulipristal acetate)
Uterine Fibroids
Phase 3 trial to be initiated 2019.
ABICIPAR
Diabetic macular edema (DME)
Phase 3 data due 2020.
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)
BLA acceptance of filing announced September 9, 2019. Estimated PDUFA date July 9, 2020.
ABICIPAR
Age-related macular degeneration (AMD)
sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI)
Approved January 19, 2017.
Oxymetazoline HCl cream 1.0%
Facial Erythema (Redness) Associated with Rosacea
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
FDA Approval announced October 2, 2018.
Sarecycline
Severe acne vulgaris
FDA Approval announced May 28, 2019.
Cariprazine
Bipolar I Depression
NDA acceptance announced March 11, 2019. PDUFA December 2019. No exact date provided.
UBROGEPANT
Migraine
Phase 2/3 trial ongoing.
Brazikumab
Ulcerative colitis
Phase 3 trial to be initiated 2H 2018.
Brimo DDS
Geographic atrophy
PDUFA date 1H 2020. No exact date announced. Estimate May 15, 2020.
Bimatoprost
Open-angle glaucoma or ocular hypertension
FDA Approval announced March 18, 2019.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI) - pediatric
FDA Approval announced October 24, 2019.
Botox
Lower limb spasticity
FDA Approval announced June 21, 2019.
Botox
Upper limb spasticity
Phase 2 top-line data due 2H 2019.
AGN-241751
Major Depressive Disorder (MDD)
Phase 3 top-line data due 2020.
Presbysol
Presbyopia
Phase 2 monotherapy interim analysis 2H 2019.
RAPASTINEL
Depression
FDA Approval announced September 3, 2019.
Juvéderm VOLUMA
Mid-Face Injection Via Cannula

Latest News

  1. Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine

    DUBLIN, Dec. 4, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the efficacy, safety and tolerability of

  2. Announcement under the Irish Takeover Rules: Relevant Securities in Issue - November 29, 2019

    DUBLIN, Nov. 29, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE

  3. Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in The Journal of the American Medical Association

    DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that positive results from ACHIEVE II (UBR-MD-02), a pivotal Phase 3 clinical trial evaluating the efficacy, safety and tolerability of

  4. Allergan® Announces First Annual National BOTOX® Cosmetic (onabotulinumtoxinA) Day

    DUBLIN, Nov. 18, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN), the maker of BOTOX® Cosmetic, has announced the first-ever National BOTOX® Cosmetic Day kicking off on November 20. The celebration recognizes the impact

  5. Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

    - Exicure to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones - Exicure to Host Conference Call Today at 8:30am ET/7:30am CT Exicure, Inc., (NASDAQ:XCUR) a pioneer in gene regulatory

  6. Allergan Receives FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation For ATM-AVI (Aztreonam And Avibactam) For Antibiotic-Resistant Gram-Negative Infections

    DUBLIN, Nov. 11, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation and Fast Track Designation for

  7. FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs

    SAN FRANCISCO and DUBLIN, Oct. 28, 2019 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, and Allergan plc (NYSE:AGN), a leading global

  8. Allergan Declares Fourth Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share

    DUBLIN, Oct. 25, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the fourth quarter of 2019. The dividend will be paid

  9. FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy

    DUBLIN, Oct. 24, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) for BOTOX® for

  10. Allergan Presents Data From Eleven Abstracts At The 2019 American Society for Dermatologic Surgery (ASDS) in Chicago

    DUBLIN, Oct. 23, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that its data will be featured during the 2019 American Society for Dermatologic Surgery Annual Meeting in Chicago, IL October 24-27 2019.

  11. Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

    DUBLIN, Oct. 11, 2019 /PRNewswire/ -- Allergan plc, (NYSE:AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (SIX: MOLN), a clinical-stage

  12. On World Sight Day, Allergan Launches National Campaign to Raise Awareness of the Toll Glaucoma Takes on Everyday Living

    DUBLIN, Oct. 10, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced a national education campaign called My Glaucoma.

  13. On World Sight Day, Allergan Launches National Campaign to Raise Awareness of the Toll Glaucoma Takes on Everyday Living

    DUBLIN, Oct. 10, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced a national education campaign called My Glaucoma.

  14. Allergan Expands REFRESH® Portfolio With New REFRESH® RELIEVA™ Lubricant Eye Drop Product Line

    DUBLIN, Oct. 7, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in eye care, today announced the launch of three new over-the-counter (OTC)

  15. Late-Stage Data from Abicipar in Age-Related Macular Degeneration to be Showcased at American Academy of Ophthalmology (AAO) Annual Meeting

    ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 4, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced

  16. Allergan to Showcase Late-Stage Data in Age-Related Macular Degeneration and Glaucoma at American Academy of Ophthalmology Annual Meeting

    DUBLIN, Oct. 3, 2019 /PRNewswire/ -- Allergan plc, (NYSE:AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology, will present new data from investigational Abicipar and

  17. Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction

    DUBLIN, Sept. 27, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS

  18. AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction

    NORTH CHICAGO, Ill., Sept. 27, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that, as expected, AbbVie and Allergan (NYSE:AGN) have each received a Request

  19. Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman

    Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.

  20. SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies Is Fair to Shareholders – AGN, ORIT, MCRN, GHDX

    NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Allergan plc (NYSE:AGN)The investigation concerns whether Allergan

  21. Announcement under the Irish Takeover Rules: Relevant Securities in Issue - September 17, 2019

    DUBLIN, Sept. 17, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE

  22. Allergan Announces Commencement of Mailing of Proxy Statement

    DUBLIN, Sept. 17, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE

  23. Allergan Shareholder Meetings Scheduled for October 14, 2019

    DUBLIN, Sept. 10, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE

  24. Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration

    DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology

  25. Allergan Receives FDA Approval of Juvéderm VOLUMA® XC For Mid-Face Injection Via Cannula

    DUBLIN, Sept. 3, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) announced today it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA® XC, a hyaluronic acid gel dermal filler, with a

  26. Allergan Announces Settlement with Two Ohio Plaintiffs in Federal Opioid Litigation

    DUBLIN, Aug. 30, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that the Company and its U.S. subsidiaries have reached a settlement with plaintiffs scheduled for trial in October 2019 in the federal opioid

  27. Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)

    THOUSAND OAKS, Calif., Aug. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP